NTLA

+ Watchlist + Portfolio

Intellia Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $13.28
52-Week Range: $7.95 – $28.25
Market Cap: $1.74B
P/E (TTM): —
EPS (TTM): -3.34
Dividend Yield: —

Advanced Metrics

Price/Book: 2.39
PEG Ratio: —
Return on Equity: -55.44%
Return on Assets: -30.14%
Gross Margin: 0.00%
Operating Margin: -1472.26%
Profit Margin: 0.00%
Current Ratio: 6.65
Debt/Equity: 0.10
Total Debt: $73.41M
Free Cash Flow: $-249.83M
Revenue Growth: -46.20%
Earnings Growth: —
Enterprise Value: $1.38B

NTLA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$52.12M	$36.27M	$57.88M	$67.67M
Research & Development	$419.98M	$435.07M	$466.31M	$388.86M
Selling, General & Admin	$90.31M	$116.50M	$125.83M	$119.80M
Operating Expenses	$510.29M	$551.57M	$592.14M	$508.66M
Operating Income	-$458.16M	-$515.29M	-$534.26M	-$440.99M
EBITDA	-$450.59M	-$506.31M	-$523.98M	-$425.07M
Pretax Income	-$474.19M	-$481.19M	-$519.02M	-$412.69M
Net Income	-$474.19M	-$481.19M	-$519.02M	-$412.69M
Diluted EPS	-6.16	-5.42	-5.25	-3.81
Diluted Shares	76.97M	88.77M	98.85M	108.38M

NTLA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$523.51M	$226.75M	$189.18M	$155.46M
Receivables	$3.77M	$36.46M	$8.52M	$9.47M
Current Assets	$1.22B	$998.33M	$639.86M	$527.71M
Total Assets	$1.52B	$1.30B	$1.19B	$842.13M
Current Liabilities	$126.55M	$115.21M	$110.85M	$103.88M
Total Debt	$130.70M	$115.35M	$210.20M	$93.33M
Total Liabilities	$284.53M	$250.81M	$319.06M	$170.73M
Retained Earnings	-$1.18B	-$1.66B	-$2.18B	-$2.59B
Shareholders' Equity	$1.24B	$1.05B	$871.96M	$671.39M
Working Capital	$1.09B	$883.12M	$529.01M	$423.83M

NTLA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$333.29M	-$394.09M	-$348.88M	-$394.74M
Capital Expenditure	-$58.39M	-$13.98M	-$5.78M	-$1.13M
Free Cash Flow	-$391.68M	-$408.07M	-$354.66M	-$395.87M
Depreciation & Amortisation	$7.57M	$8.98M	$10.29M	$15.92M
Stock-Based Compensation	$91.40M	$134.05M	$154.27M	$80.22M
Investing Cash Flow	$160.31M	-$31.35M	$125.57M	$228.03M
Financing Cash Flow	$582.96M	$130.32M	$185.75M	$131.49M
Net Change in Cash	$409.98M	-$295.11M	-$37.57M	-$35.22M

NTLA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$16.63M	$14.24M	$13.78M	$23.02M	$15.05M
Research & Development	$108.43M	$97.03M	$94.75M	$88.65M	$80.74M
Selling, General & Admin	$29.01M	$27.21M	$30.51M	$33.08M	$34.84M
Operating Expenses	$137.43M	$124.24M	$125.26M	$121.73M	$115.58M
Operating Income	-$120.81M	-$110.00M	-$111.48M	-$98.71M	-$100.53M
EBITDA	-$118.31M	-$107.52M	-$106.54M	-$92.69M	-$98.33M
Pretax Income	-$114.33M	-$101.25M	-$101.32M	-$95.79M	-$96.23M
Net Income	-$114.33M	-$101.25M	-$101.32M	-$95.79M	-$96.23M
Diluted EPS	-1.10	-0.98	-0.92	-0.83	-0.81
Diluted Shares	103.50M	103.73M	110.19M	115.92M	118.49M

NTLA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$126.88M	$156.17M	$193.39M	$155.46M	$134.70M
Receivables	$10.50M	$11.35M	$11.05M	$9.47M	$9.13M
Current Assets	$551.39M	$495.94M	$581.94M	$527.71M	$466.45M
Total Assets	$986.16M	$898.89M	$925.27M	$842.13M	$758.78M
Current Liabilities	$112.59M	$95.50M	$93.73M	$103.88M	$76.44M
Total Debt	$119.25M	$102.59M	$97.97M	$93.33M	$80.49M
Total Liabilities	$206.24M	$183.64M	$176.85M	$170.73M	$137.84M
Retained Earnings	-$2.29B	-$2.39B	-$2.49B	-$2.59B	-$2.69B
Shareholders' Equity	$779.92M	$715.25M	$748.42M	$671.39M	$620.94M
Working Capital	$438.80M	$400.45M	$488.21M	$423.83M	$390.00M

NTLA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$148.93M	-$99.62M	-$76.90M	-$69.28M	-$117.35M
Capital Expenditure	-$735.00K	-$239.00K	-$29.00K	-$126.00K	-$79.00K
Free Cash Flow	-$149.66M	-$99.86M	-$76.93M	-$69.41M	-$117.42M
Depreciation & Amortisation	$2.50M	$2.47M	$4.94M	$6.01M	$2.20M
Stock-Based Compensation	$21.84M	$22.04M	$19.60M	$16.74M	$13.48M
Investing Cash Flow	$94.33M	$106.91M	-$741.00K	$27.53M	$66.31M
Financing Cash Flow	$0.00	$14.65M	$114.86M	$1.98M	$33.57M
Net Change in Cash	-$54.60M	$21.94M	$37.22M	-$39.77M	-$17.47M

Market Snapshot

About

Intellia Therapeutics is a leading genome editing company developing CRISPR/Cas9-based therapies to treat genetic diseases. The company is advancing both in vivo (directly in the body) and ex vivo (cell therapy) programs targeting conditions including transthyretin amyloidosis, hereditary angioedema, and various cancers using its proprietary CRISPR platform.